Kiernan Jane E 4
4 · Axonics, Inc. · Filed Nov 15, 2024
Insider Transaction Report
Form 4
Axonics, Inc.AXNX
Kiernan Jane E
Director
Transactions
- Disposition to Issuer
Common Stock
2024-11-15$71.00/sh−19,861$1,410,131→ 0 total
Footnotes (1)
- [F1]Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The "Merger Consideration").